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The Community Preventive Services Task Force recommends re-
ducing patient out-of-pocket costs (ROPC) for medications to con-
trol high blood pressure and high cholesterol when combined with
additional interventions aimed at improving patient–provider in-
teraction and patient knowledge, such as team-based care with
medication counseling, and patient education.
This recommendation is based on strong evidence of effectiveness
in improving medication adherence and outcomes for high blood
pressure and cholesterol. Limited evidence was available to assess
the effectiveness of reducing patient out-of-pocket costs for beha-
vioral counseling or behavioral support services independent of re-
ducing patient  costs  for  medications.  A summary of  the  Task
Force finding and rationale is at www.thecommunityguide.org/
cvd/ROPC.html.
Definition
Reducing out-of-pocket costs (ROPC) for patients with high blood
pressure  and  high  cholesterol  involves  program  and  policy
changes that make medications for cardiovascular disease (CVD)
prevention more affordable. Costs for treatment medications can
be reduced by providing new or expanded treatment coverage and
lowering or eliminating patient out-of-pocket expenses (eg, copay-
ments, coinsurances, deductibles).
Reducing out-of-pocket costs is coordinated through the health
care system, and preventive services may be delivered in clinical
or nonclinical settings (eg, worksite, community). ROPC can be
implemented alone or in combination with additional interven-
tions to enhance patient–provider interaction such as team-based
care, medication counseling, and patient education. Program and
policy changes may be communicated to patients and providers
using targeted messages to increase awareness and use of covered
services.
Basis of Finding
The Task Force finding is based on evidence from 18 studies (pub-
lished from January 1980 to July 2015) that assessed the effective-
ness of reducing out-of-pocket costs for medications to treat high
blood pressure, high cholesterol, or both (1). All 18 studies evalu-
ated programs or policies that reduced patient out-of-pocket costs
for medications to treat high blood pressure or high cholesterol.
Ten studies combined ROPC for medications with one or more ad-
ditional interventions including team-based care with medication
counseling (7 studies), proactive follow-up (5 studies), linkages to
other resources and services (4 studies), disease management (3
studies), and patient education (4 studies). Nine of 18 studies as-
sessed the impact of ROPC for medications on blood pressure and
cholesterol outcomes. Six studies assessed the impact of ROPC on
adherence to blood pressure- and cholesterol-lowering medica-
tions. Only one of 18 studies evaluated the impact of both medica-
tion  adherence  and  blood  pressure  and  cholesterol  outcomes.
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Twelve studies were policy-based; 7 of these evaluated value-
based insurance design (VBID).
The Task Force finding reflects 1) the focus of available studies on
ROPC for  medications,  2)  meaningful  improvements  in blood
pressure and cholesterol outcomes (median decrease of 5.9 and
3.75 mm Hg in systolic and diastolic blood pressure, respectively,
in 4 studies and a reduction of 15 mg/dL in 1 study) in patients
from studies in which most ROPC efforts were combined with ad-
ditional interventions such as team-based care with medication
counseling,  3)  modest  improvements  in  medication adherence
(median adherence for all 15 blood pressure and lipid-lowering
medications increased 3.0 percentage points in 6 studies) in stud-
ies with ROPC policy changes, and 4) the lack of studies includ-
ing or evaluating ROPC for behavioral counseling or behavioral
support services for patients with high blood pressure or high cho-
lesterol, independent of ROPC for medications.
Applicability
Fifteen of the 18 studies were conducted in the United States with
study populations that included working-age adults balanced by
sex.  Studies  examined outcomes in different  racial  and ethnic
groups (ie, Hispanic, white, and African American) with similar
results.  Six studies found effectiveness of ROPC in improving
treatment outcomes for low-income patients. Overall, results in-
dicate that ROPC is effective in a wide range of patients with high
blood pressure and high cholesterol in the US health care system.
Evidence also shows applicability to diverse policy and program
implementers, such as employers and government agencies.
ROPC can be coordinated with other interventions (eg, medica-
tion counseling) with the goal of increasing opportunities for pa-
tient–provider interaction on treatment issues such as medication
side effects. No harms to patients from these interventions were
identified in the included studies or the broader literature.
Economic Evidence
The systematic economic review of the intervention included 9
studies that evaluated ROPC for medications to treat high blood
pressure or high cholesterol. Seven of these were for reductions in
medication costs as part of VBID plans. Two of the 9 studies com-
bined reduced cost for medications with team-based care and 3
studies combined reduced medication cost with coaching for life-
style or disease management. However, only one of the studies of
these combined interventions provided the cost to implement both
the ROPC and the added component.
Five of the 7 studies that estimated the effect of the intervention on
nonpharmacy health care cost indicated these costs were reduced.
The time frame of these analyses ranged from 5 years of follow-up
to 1 year, with most in the 1- to 2-year range. Three studies that
assessed net benefit of change in health care cost minus interven-
tion cost indicated mixed results, one showing the intervention
was cost-neutral and 2 indicating they were cost-increasing. No
studies reported cost-effectiveness outcomes. An overall econom-
ic conclusion about the intervention cannot be drawn from this
small and inconsistent body of cost-benefit evidence.
Considerations for Implementation
This Task Force finding supports incorporation of policies or pro-
grams to reduce or eliminate out-of-pocket costs for medications
to treat patients with high blood pressure or high cholesterol as
one part  of  an effort  to prevent cardiovascular  disease.  Team-
based care and disease management programs were common addi-
tional interventions evaluated in the reviewed studies; broader
health system efforts such as Patient-Centered Medical Homes
could also provide a useful infrastructure to coordinate prevention
activities. In addition, partnerships with employers, providers, and
community-based organizations may provide resources and set-
tings that enhance access to and use of preventive services.
Potential implementers include health care providers and plans,
government agencies, and self-insured and fully insured employ-
ers. Review results suggest opportunities for innovative applica-
tion of ROPC policies, coordination of programs, and partner-
ships  for  delivery of  services.  Linking medical  and pharmacy
claims data and other information systems across settings may en-
hance coordinated service delivery, monitoring of service use, and
assessment of program effectiveness for multiple outcomes of in-
terest.
To increase awareness and use of ROPC covered services, it is
critical to promote ROPC benefits to patients and providers. Only
3 of 18 included studies described communicating available bene-
fits for reducing out-of-pocket medication costs to patients via let-
ter, newsletter, or company intranet. No reviewed studies evalu-
ated or reported changes in awareness resulting from activities to
communicate ROPC benefits.
Low-income patients experienced improved blood pressure and
cholesterol outcomes after being treated with a combination of in-
terventions including ROPC for medications. Implementers should
consider promotion strategies that are innovative, culturally appro-
priate,  and targeted to  increase  awareness  among low-income
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groups  with  low medication  adherence.  Partnering  with  com-
munity organizations can also provide opportunities to increase
awareness and use of ROPC benefits among underserved popula-
tions.
One ROPC policy approach is to reduce or eliminate copayments
for generic medications. Providers may need to discuss appropri-
ate generic medications with their patients. Prescribing providers
can be important advocates for patients unaware of ROPC bene-
fits. Providers can 1) ask patients about their ability to pay for
medications and 2) be familiar with medications covered by pa-
tients’ health insurance plans and the costs to patients.
Reducing out-of-pocket costs for patients with high blood pres-
sure and high cholesterol can be implemented as part of a broader
effort to increase use of effective cardiovascular disease prevent-
ive services. Evidence in the review, including studies evaluating
VBID, indicates ROPC interventions are effective in increasing
adherence to medications in patients with different cardiovascular
risk conditions. A comprehensive approach, for example, could
coordinate ROPC for medications to improve blood pressure and
cholesterol outcomes with evidence-based tobacco cessation treat-
ments, coverage to improve management of patients with diabetes,
or both. The Affordable Care Act, recognizing the potential of
VBID plans to improve patient receipt of preventive health ser-
vices without cost-sharing (2), provides opportunities to reduce
patients’ out-of-pocket costs and assist in preventing cardiovascu-
lar disease through a section of the law featuring VBID and call-
ing for health plan coverage of preventive health services (3).
Evidence Gaps
Although evidence indicates effectiveness of ROPC for medica-
tions to control high blood pressure and high cholesterol, addition-
al research should take into account the assessment of ROPC in
other areas of cardiovascular disease preventive services (eg, be-
havioral counseling), especially when coordinated with ROPC for
medications. Future studies should also describe efforts to effect-
ively communicate the presence and availability of covered ROPC
benefits and evaluate both the reach and effectiveness of different
communication techniques. Relationships between cost reduction
and  patient  use  must  be  examined,  providing  evidence  on
thresholds and differential  effectiveness.  In addition,  research
could examine effectiveness of ROPC by total medication cost,
proportional cost-reduction, patient income, or drug patent type.
In general, policy studies included in this review examined the im-
pact of adding ROPC for medications for an entire patient popula-
tion but evaluated only changes in medication adherence. Con-
versely, the studies evaluating multicomponent programs that in-
clude ROPC for medications examined clinical outcomes for pa-
tients in the program but did not report on changes in medication
adherence. Both outcomes provide useful information to potential
implementers and should be reported together.
There are very few complete economic evaluations of ROPC inter-
ventions for cardiovascular disease prevention services. Less than
half of the interventions evaluated for effectiveness included any
assessment of economic costs or benefits. Cost-effectiveness could
not be calculated for VBID plans because their evaluations did not
report clinical outcomes such as changes in blood pressure. The
cost of communicating the ROPC benefits to providers and pa-
tients was not discussed or estimated in any of the economic stud-
ies.
Research efforts in these areas can improve understanding of the
ways in which ROPC for medications to treat high blood pressure,
high cholesterol, or both can help improve patient health.
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